| |
Dear Colleagues,
GTCBio is proud to introduce our 6th Annual Cancer Drugs Research and Development conference, which is scheduled to be held in Philadelphia, PA on Feb 19-20, 2009. Last year’s conference was a great success with leaders in oncology R&D from organizations such as GSK, AstraZeneca, Pfizer, Novartis, Abbott, Millenium, and Wyeth gather to discuss novel developments and successful achievements in this area. We covered a range of topics from new drug compounds for cancer prevention to new delivery methods of targeted therapeutics.
This year, we will analyze case studies of the successes and challenges of modern Cancer Drugs and provide you with an update on Cancer Drugs currently in development through clinical trials. A look at novel compound and emerging targets will prime you with the future outlook of cancer drugs with key topics to be discussed by leading experts including the use of biomarkers, mTOR inhibitors, angiogenesis, PARP inhibitors, PI3K inhibitors, RNAi targets, VEGF Receptor inhibitors, and much more. The new frontier of combination therapeutics and therapies will be also covered in detail.
The sessions will cover the following:
- Challenges and Successes of Modern Cancer Drugs
- Cancer Drug Discovery Strategies
- Novel Compounds and Emerging Targets
- Combination Therapies for Cancer Treatment
- Cancer Drugs in Clinical Trials
Please click here for a detailed agenda.
Learn, brainstorm and collaborate with your colleagues in the industry. Sign up today!
We look forward to seeing you in Philadelphia.
Best regards,
2009 Cancer Drugs Organizing Committee
 |
Attend ONE additional Conference of your choice for only $400 more. Click here to sign up!
|
| |
|
 |
Attend ALL 2009 GTCbio Conferences for only $3000.
Click here to sign up!
|
|
Keynote Speakers:
|